Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1888-1894

  Jacobson, Jennie G ^a   Renau, Thomas E ^a,b   Nassiri, M Reza ^a,c   Sweier, Dominica G ^a   Breitenbach, Julie M ^a   Townsend, Leroy B ^a   Drach, John C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Microcide Pharmaceuticals Inc   (United States)

^c LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 4 (4 METHOXYBENZYL)PYRROLO[2,3 D]PYRIMIDINE 5 THIOCARBOXAMIDE; 4 AMINO 7 [(2 METHOXYETHOXY)METHYL]PYRROLO[2,3 D]PYRIMIDINE 5 THIOCARBOXAMIDE; 5 CYANO 4,6 DIAMINO 7 (4 METHYLBENZYL)PYRROLO[2,3 D]PYRIMIDINE; ANTIVIRUS AGENT; GANCICLOVIR; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; PRIORITY JOURNAL; SKIN FIBROBLAST; STRUCTURE ACTIVITY RELATION; VIRUS ADSORPTION; VIRUS INHIBITION;

EID: 0032818692     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1888     Document Type: Article

References (48)

1. AIDS Research Group. 1992. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med. 326:203-220.
2. Andrei, G., D. Schols, R. Snoeck, A. Bugnicourt, C. Nemecek, E. De Clercq, and C. Roy. 1998. RPR CMV423 inhibits replication of HCMV at an early step of the virus replicative cycle, abstr. H-84, p. 339. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Birch, G. M., S. H. Krawczyk, L. B. Townsend, and J. C. Drach. 1989. Antagonism of the cytotoxic hut not antiviral effects of ara-sangivamycin by adenosine. Antimicrob. Agents Chemother. 35:1606-1608.
4. Biron, K. K., S. C. Stant, J. B. Sorrell, J. A. Fyfe, P. M. Keller, C. U. Lambe, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:2473-2477.
5. Biron, K. K. 1991. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant. Proc. 23(Suppl. 3):162-167.
6. Biron, K. K. Personal communication.
7. Britt, W. J., and C. A. Alford. 1996. Cytomegalovirus, p. 2493-2523. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
8. Chrisp, P., and S. P. Clissold. 1991. Foscarnet: a review of its antiviral activity, pharmacokinetic properties, and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
9. Crumpacker, C. S. 1996. Ganciclovir. Drug Ther. 355:720-729.
10. Danker, W. M., D. Scholl, S. C. Stanat, M. Martin, R. L. Sonke, and S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28:293-298.
11. Davis, M. G., S. C. Kenney, J. Kamine, J. S. Pagano, and E. S. Huang. 1987 Immediate early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84:8642-8646.
12. DeClerq, E., A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.
13. Deray, G., F. Martinez, C. Katlama, B. Levaltier, H. Beaufils, M. Danis, M. Rozenheim, A. Baumelou, E. Dohin, M. Gentilini, and C. Jacobs. 1989. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. 9:316-320.
14. Elliot, G., and P. O'Hare. 1997. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223-235.
15. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, and M. C. Jordan, Jr. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
16. Greaves, R. F., and E. S. Mocarski. 1998. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human ieI mutant. J. Virol. 72:366-379.
17. Gupta, P. K., S. Daunert, M. R. Nassiri, L. L. Wotring, J. C. Drach, and L. B. Townsend. 1989. Synthesis, cytotoxicity and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin and sangivamycin. J. Med. Chem. 32:402-408.
18. Hitchcock, M. J. M., H. S. Jaffe, J. C. Martin, and R. J. Stagg. 1996. Cidofovir, a new agent with potent anti-herpesvirus activity. Antimicrob. Agents Chemother. 7:115-127.
19. Jacobson, M. A., J. G. Gambertoglio, F. T. Aweeka, D. M. Causey, and A. A. Portale. 1991. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J. Clin. Endocrinol. Metab. 72:1130-1135.
20. Knox, K. K., W. R. Drobyski, and D. R. Carrigan. 1991. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 357:1292-1293.
21. Lewis, A. F., J. C. Drach, S. M. Fennewald, J. H. Huffman, R. G. Ptak, J.-P. Sommadossi, G. R. Revankar, and R. F. Rando. 1994. Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo [4,5-d]pyrimidine ring system. Antimicrob. Agents Chemother. 38:2889-2895.
22. Loomis, C. R., and R. M. Bell. 1988. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J. Biol. Chem. 283:1682-1692.
23. Marwick, C. 1998. First "antisense" drug will treat CMV retinitis. JAMA 280:871.
24. Mills, J., and H. Masur. 1990. AIDS-related infections. Sci. Am. 263:50-57.
25. Nassiri, M. R., J. L. Hudson, J. S. Pudlo, G. M. Birch, L. B. Townsend, and J. C. Drach. 1990. Flow cytometric evaluation of the cytotoxicity of novel antiviral compounds. Cytometry 11:411-417.
26. Nassiri, M. R., S. G. Emerson, R. V. Devivar, L. B. Townsend, J. C. Drach, and R. S. Taichman. 1996. Comparison of benzimidazole nucleosides and ganciclovir on the in vitro proliferation and colony formation of human bone marrow progenitor cells. Br. J. Haematol. 93:273-279.
27. Osada, H., T. Sonoda, K. Tsunoda, and K. Isono. 1989. A new biological role of sangivamycin: inhibition of protein kinases. J. Antibiot. 42:102-106.
28. Pajovic, S., E. L. Wong, A. R. Black, and J. C. Azizkhan. 1997. Identification of a viral kinase that phosphorylates specific E2Fs and pocket proteins. Mol. Cell. Biol. 17:6459-6464.
29. Palestine, A. G., M. A. Polis, M. De Smet, B. F. Baird, J. Falloon, J. A. Kovacs, R. T. Davey, J. J. Zurlo, K. M. Zunich, M. Davis, L. Hubbard, R. Brothers, F. L. Ferris, E. Chew, J. L. Davis, B. I. Rubin, S. D. Mellow, J. A. Metcalf, J. Mansichewitz, J. R. Minor, R. B. Nussenblatt, H. Masur, and H. C. Lane. 1991. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115:665-673.
30. Peters, B. S., E. J. Beck, S. Anderson, D. Coleman, R. Coker, J. Main, C. Migdal, J. R. W. Harris, and A. J. Pinching. 1991. Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. J. Infect. 23:129-137.
31. Prichard, M. N., S. R. Turk, L. A. Coleman, S. L. Engelhardt, C. Shipman, Jr., and J. C. Drach. 1990. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods 28:101-106.
32. Prichard, M. N., and C. Shipman, Jr. 1990. A three dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-206.
33. Prichard, M. N., L. E. Prichard, W. A. Baguley, M. R. Nassiri, and C. Shipman, Jr. 1991. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob. Agents Chemother. 35:1060-1065.
34. Renau, T. E., M. R. Nassiri, E. E. Swayze, L. B. Townsend, and J. C. Drach. 1992. Improved synthesis and biological evaluation of an acyclic thiosangivamycin active against human cytomegalovirus. Antivir. Res. 19:15-28.
35. Renau, T. E., M. S. Ludwig, J. C. Drach, and L. B. Townsend. 1992. Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin, sangivamycin, and thiosangivamycin. Bioorg. Med. Chem. Lett. 2:1755-1760.
36. Renau, T. E., J. S. Lee, H. Kim, C. G. Young, L. L. Wotring, L. B. Townsend, and J. C. Drach. 1994. Relationship between cytotoxicity and conversion of thiosangivamycin analogs to toyocamycin analogs in cell culture medium. Biochem. Pharmacol. 48:801-807.
37. Renau, T. E., L. L. Wotring, J. C. Drach, and L. B. Townsend. 1996. Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: influence of various 7-substituents on antiviral activity. J. Med. Chem. 39:873-880.
38. Renau, T. E., C. Kennedy, R. G. Ptak, J. Breitenbach, J. C. Drach, and L. B. Townsend. 1995. Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4-and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines. J. Med. Chem. 39:3470-3476.
39. Rubin, R. H. 1990. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12:S754-S766.
40. Saxena, N. K., L. A. Coleman, J. C. Drach, and L. B. Townsend. 1990. Synthesis and antiviral activity of some 7-(2-hydroxyethoxymethyl)pyrazolo[3,4-d]pyrimidine analogs of sangivamycin and toyocamycin. J. Med. Chem. 35:1980-1983.
41. Shepp, D. H., P. S. Dandliker, P. de Miranda, T. C. Burnette, D. M. Cederberg, L. E. Kirk, and J. D. Meyers. 1985. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 103:368-373.
42. Shipman, C., Jr. 1969. Evaluation of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) as a tissue culture buffer. Proc. Soc. Exp. Biol. 130:305-310.
43. Stratta, R. J., M. S. Shaeffer, R. S. Markin, R. P. Wood, A. N. Langnas, E. C. Reed, J. P. Donovan, G. L. Woods, K. A. Bradshaw, T. J. Pillen, and B. W. Shaw, Jr. 1992. Cytomegalovirus infection disease after liver transplantation. Dig. Dis. Sci. 37:673-688.
44. Sullivan, V., and D. Coen. 1991. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J. Infect. Dis. 164:781-784.
45. Swayze, E. E., W. M. Shannon, R. W. Buckheit, L. L. Wotring, J. C. Drach, and L. B. Townsend. 1992. Synthesis, antiproliferative and antiviral evaluation of certain acyclic 6-substituted pyrrolo[2,3-d]pyrimidine nucleoside analogs related to sangivamycin and toyocamycin. Nucleosides Nucleotides 11:1507-1527.
46. Townsend, L. B., J. C. Drach, L. L. Wotring, S. Vittori, J. S. Pudlo, E. E. Swayze, P. Gupta, T. Maruyama, N. Saxena, L. A. Coleman, A. C. Westerman, J. Spurr, M. R. Nassiri, S. R. Turk, and S. H. Krawczyk. 1991. Design, synthesis and studies on the structure activity relationships of certain pyrrolo[2,3-d]pyrimidine nucleosides and structurally related analogs as potential antineoplastic and antiviral agents. Il Farmaco 46:113-139.
47. Turk, S. R., C. Shipman, Jr., M. R. Nassiri, G. Genzlinger, S. H. Krawczyk, L. B. Townsend, and J. C. Drach. 1987. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 31:544-550.
48. Webster, A. 1991. Cytomegalovirus as a possible cofactor in HIV disease progression. J. Acquired Immune Defic. Syndr. 4:S47-S52.